Huntington's disease (HD) is a late-onset neurodegenerative disease for which the mutation is CAG/polyglutamine repeat expansion. The R6 mouse lines expressing the HD mutation develop a movement disorder that is preceded by the formation of neuronal polyglutamine aggregates. The phenotype is likely caused by a widespread neuronal dysfunction, whereas neuronal cell death occurs late and is very selective. We show that a decreased mRNA level of the major astroglial glutamate transporter (GLT1) in the striatum and cortex of these mice is accompanied by a concomitant decrease in glutamate uptake. In contrast, the expression of the glutamate transporters, GLAST and EAAC1, remain unchanged. The mRNA level of the astroglial enzyme glutamine synthetase is also decreased. These changes in expression occur prior to any evidence of neurodegeneration and suggest that a defect in astrocytic glutamate uptake may contribute to the phenotype and neuronal cell death in HD.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder with symptoms that include a movement disorder, psychiatric disturbances, and cognitive impairment (Harper, 1996) . The neuropathology can be divided into three categories: a selective neuronal cell loss that is most pronounced in the striatum with an accompanying astrogliosis (Vonsattel et al., 1985) , a widespread atrophy that occurs across all brain regions (de la Monte et al., 1988) , and a polyglutamine (polyQ) aggregate pathology. PolyQ aggregates most likely contain a truncated version of huntingtin and can appear in the form of neuronal intranuclear inclusions, dystrophic neurites, and neuropil aggregates (Becher et al., 1998; DiFiglia et al., 1997; Gutekunst et al., 1999) .
The HD mutation is a CAG repeat expansion that results in the increased length of a stretch of polyQ residues in the huntingtin protein (Huntington's Disease Collaborative Research Group (HDCRG), 1993). Unaffected individuals carry repeats ranging from 6 to 35 CAGs and the pathogenic range starts at 36 (Myers et al., 1998) . Huntingtin can therefore tolerate a wide variation in the length of this polyQ tract, which at a sharp threshold becomes pathogenic. The only molecular property thus far shown to correlate with this CAG repeat threshold is an increase in the rate at which exon 1 huntingtin can form amyloid fibrils in vitro (Scherzinger et al., 1997 (Scherzinger et al., , 1999 . Currently, the mechanism by which the mutation leads to cellular dysfunction and cell death is unknown.
Major insights into the molecular basis of HD have arisen from mouse models, the most extensively characterized of which are the R6 lines containing an exon 1 huntingtin transgene (Mangiarini et al., 1996) . Lines R6/1 and R6/2 have CAG repeats of approximately 115 and 150 (Mangiarini et al., 1997) and onset ages of around 2 and 4 -5 months, respectively, as determined by home-cage observations. The relative onset and progression of the phenotype and neuropathology has been determined in most detail for line R6/2. In this line, motor impairments can be detected by 5 weeks using various tests of motor function (Carter et al., 1999) . PolyQ aggregates are present in nuclei and the neuropil prior to 4 weeks of age in some brain regions
